Novartis will fund all further product development and marketing expenses in the approval process under a worldwide license (excluding Canada) to market the chirally pure version of Ritalin (methylphenidate). Celgene expects to file the d-methylphenidate NDA for treatment of attention deficit disorder during the third quarter. The chiral product will carry a Ritalin family name. Celgene's previous name for the d-methylphenidate product, Attenade, will no longer be used
You may also be interested in...
Novartis' Focalin will be priced similarly to its parent compound Ritalin, the company said following the Nov. 13 approval of the attention deficit hyperactivity disorder drug
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011